2015 WEB Version World Cord Blood Congress Press Announcement

2015 World Cord Blood Congress Taps CariCord President/CEO and Executive Director as Keynote Speakers

May 19, 2015 – Irvine, CA – The World Cord Blood Congress will take place in London next week and over the two-day period hundreds of professionals in the cord blood community will hear from approximately 30 speakers on a variety of topics related to cord blood and the future of regenerative medicine. On the first day following opening remarks, attendees will hear from Calvin Cole, President and Chief Executive Officer of CariCord, Inc. and Brian Freed, M.D., Executive Director of Clinimmune Labs and CariCord at University of Colorado.

Mr. Cole and Dr. Freed will present jointly at the event on the topic of new business models for the cord blood industry, particularly combining public and private banks. In their talk, Mr. Cole and Dr. Freed will share perspective on:

  • How to serve private consumers while sustaining efforts to build the National Cord Blood Inventory.
  • How partnerships create a more sustainable pathway that is responsive to current and future private and federal sector demands.
  • Key challenges in combining private with an existing public bank.
  • How the standard of quality processing and storage of umbilical cord stem cell products dictate the success of a business model.

CariCord, Inc. is the private cord blood bank of University of Colorado's highly accredited ClinImmune Labs. Through the exclusive public-private cord blood banking venture, CariCord is the first private cord blood bank in the U.S that offers consumers cord blood and cord tissue processing and banking under pharmaceutical grade practices.

The World Cord Blood Congress aims to bring together public and private banks, clinicians, researchers, and solution providers, to tackle the challenges and opportunities facing this field of regenerative medicine and provide a platform to advance the cord blood sector.

According to the conference website, the cord blood banking industry is one of the fastest growing industries in the world, with cord blood banks increasing by 21 fold in less than 10 years. Recent challenges have meant that there are still issues that need to be addressed. High costs of acquiring units due to expensive processing and storage, a lack of available units, and a plateau in the use of cord blood for transplant mean that a meeting between key players in this area is greatly needed.

To learn more visit: http://www.terrapinn.com/conference/world-cord-blood-congress-europe/index.stm.

About CariCord, Inc.

CariCord, Inc. is a joint venture corporation of StemCC, Inc. (a privately owned Delaware Corp.) and the University of Colorado owned ClinImmune Labs. Headquartered in Irvine, CA, with exclusive processing by the FDA licensed ClinImmune Labs at the University of Colorado, School of Medicine in Aurora, CO, it is the first and only company offering private consumers cord blood banking under pharmaceutical grade practices. CariCord’s proven industry management team offers umbilical cord blood and cord tissue banking services nationwide. Its clients have the option of selecting value added HLA tissue typing. For more information please visit www.CariCord.com.